CA2297163C - Gaba analogs to prevent and treat gastrointestinal damage - Google Patents

Gaba analogs to prevent and treat gastrointestinal damage Download PDF

Info

Publication number
CA2297163C
CA2297163C CA002297163A CA2297163A CA2297163C CA 2297163 C CA2297163 C CA 2297163C CA 002297163 A CA002297163 A CA 002297163A CA 2297163 A CA2297163 A CA 2297163A CA 2297163 C CA2297163 C CA 2297163C
Authority
CA
Canada
Prior art keywords
compound
gabapentin
compound according
composition
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002297163A
Other languages
English (en)
French (fr)
Other versions
CA2297163A1 (en
Inventor
Antonio Guglietta
Charles Price Taylor Jr.
Jiayuan Ren
William Patrick Watson
Michael Francis Rafferty
Laurent Diop
Maria Chovet
Lionel Bueno
Hilary J. Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Warner Lambert Co LLC
Original Assignee
University of Oklahoma
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2297163(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Oklahoma, Warner Lambert Co LLC filed Critical University of Oklahoma
Publication of CA2297163A1 publication Critical patent/CA2297163A1/en
Application granted granted Critical
Publication of CA2297163C publication Critical patent/CA2297163C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CA002297163A 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage Expired - Lifetime CA2297163C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5675397P 1997-08-20 1997-08-20
US60/056,753 1997-08-20
US7479498P 1998-02-16 1998-02-16
US60/074,794 1998-02-16
US8293698P 1998-04-24 1998-04-24
US60/082,936 1998-04-24
PCT/US1998/017082 WO1999008671A1 (en) 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage

Publications (2)

Publication Number Publication Date
CA2297163A1 CA2297163A1 (en) 1999-02-25
CA2297163C true CA2297163C (en) 2001-11-20

Family

ID=27369092

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002297163A Expired - Lifetime CA2297163C (en) 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage

Country Status (25)

Country Link
US (2) US6242488B1 (enExample)
EP (1) EP1009399B1 (enExample)
JP (1) JP4681116B2 (enExample)
KR (2) KR100609359B1 (enExample)
AT (1) ATE461698T1 (enExample)
AU (2) AU8668598A (enExample)
BR (1) BR9812133A (enExample)
CA (1) CA2297163C (enExample)
CO (1) CO4960645A1 (enExample)
CY (1) CY1109981T1 (enExample)
DE (1) DE69841574D1 (enExample)
DK (1) DK1009399T3 (enExample)
ES (1) ES2341154T3 (enExample)
HU (1) HUP0004551A3 (enExample)
IL (1) IL134164A (enExample)
IS (1) IS2749B (enExample)
MY (1) MY155223A (enExample)
NO (1) NO327983B1 (enExample)
NZ (1) NZ502729A (enExample)
PE (1) PE107299A1 (enExample)
PL (1) PL194125B1 (enExample)
PT (1) PT1009399E (enExample)
TW (2) TWI251485B (enExample)
UY (1) UY25148A1 (enExample)
WO (2) WO1999008670A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
WO1999012537A1 (en) 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1031350A1 (en) * 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
PT1202725E (pt) 1999-07-22 2007-07-11 Universuty Of Rochester Método para tratar sintomas de alteração hormonal, incluindo afrontamentos.
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
JP2003533223A (ja) * 2000-05-16 2003-11-11 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー α２δ２カルシウムチャネルサブユニットの発現細胞株
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1274306C (zh) 2001-09-03 2006-09-13 纽朗制药有限公司 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
EP1549302A1 (en) * 2002-07-10 2005-07-06 Warner-Lambert Company LLC Gastrointestinal compositions comprising gaba derivatives
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
AU2003286300A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2004078734A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
CA2538802C (en) 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
PT1727620E (pt) * 2004-03-12 2007-11-05 Warner Lambert Co Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
DE602005009161D1 (de) * 2004-04-01 2008-10-02 Warner Lambert Co Herstellung von p-chirogenen phospholanen und deren verwendung in der asymmetrischen synthese
CN1972904B (zh) * 2004-06-21 2011-02-02 沃尼尔·朗伯有限责任公司 普瑞巴林和相关化合物的制备
RS51411B (sr) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
IN266803B (enExample) 2005-12-22 2015-06-03 Newron Pharm Spa
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
CA2703472A1 (en) * 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
TWI542344B (zh) * 2009-06-22 2016-07-21 惠氏有限責任公司 異丁苯丙酸鈉錠及製備包含異丁苯丙酸鈉之醫藥組合物之方法
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
CN105997970A (zh) * 2015-12-16 2016-10-12 南昌大学 γ-氨基丁酸在制备胃粘膜保护剂中的应用
WO2017177160A1 (en) * 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
JP7249670B2 (ja) 2017-10-03 2023-03-31 ネヴァカー インジェクテーブルズ インコーポレイテッド アセトアミノフェン－プレガバリン組み合わせ及び疼痛を処置する方法
JP7441181B2 (ja) 2018-05-14 2024-02-29 エックスジーン ファーマシューティカル インク． ナプロキセンとプレガバリンの１－（アシルオキシ）－アルキルカルバメート薬品複合体の結晶形態
CN116999560A (zh) * 2022-04-30 2023-11-07 武汉思瓴生物科技有限公司 可治疗疼痛的药物组合及其应用
IL322802A (en) * 2023-02-17 2025-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634102A (enExample)
DE1963925C3 (de) 1969-12-20 1975-07-10 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins
JPS54110334A (en) 1978-02-16 1979-08-29 Fuji Chem Ind Co Ltd Novel compounded anodyne and antiiinflammatory agent
US4158581A (en) 1978-04-14 1979-06-19 Westinghouse Electric Corp. Method of making magnetic component for direct current apparatus
JPS61221121A (ja) 1985-03-27 1986-10-01 Nitto Electric Ind Co Ltd テ−プ製剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
WO1989005642A1 (en) 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en) 1991-04-18 1991-06-05 Radoslavov Alexander A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
DK0641330T3 (da) 1992-05-20 2001-12-03 Univ Northwestern Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling
US5234929A (en) 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja) 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd 徐放性組成物
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja) 1993-02-02 1994-08-16 Masayasu Sugihara 薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en) 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
MX9701477A (es) 1994-09-02 1998-02-28 Univ Virginia Commonwealth Composicion para aliviar el dolor, que contiene un analgesico no narcotico y un mejorador de analgesia.
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
CN1046199C (zh) 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
NZ334898A (en) * 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
DE69841574D1 (de) 2010-05-06
NO327983B1 (no) 2009-11-02
MY155223A (en) 2015-09-30
US6242488B1 (en) 2001-06-05
NZ502729A (en) 2002-10-25
PT1009399E (pt) 2010-05-21
CY1109981T1 (el) 2014-09-10
EP1009399B1 (en) 2010-03-24
PL194125B1 (pl) 2007-04-30
JP2001515033A (ja) 2001-09-18
PL338705A1 (en) 2000-11-20
IS2749B (is) 2011-08-15
UY25148A1 (es) 1999-01-26
WO1999008670A1 (en) 1999-02-25
ATE461698T1 (de) 2010-04-15
HUP0004551A2 (hu) 2001-05-28
DK1009399T3 (da) 2010-05-31
CA2297163A1 (en) 1999-02-25
KR100609359B1 (ko) 2006-08-04
AU9293098A (en) 1999-03-08
KR20050116168A (ko) 2005-12-09
US6426368B2 (en) 2002-07-30
NO20000786L (no) 2000-02-17
US20010014698A1 (en) 2001-08-16
BR9812133A (pt) 2000-07-18
CO4960645A1 (es) 2000-09-25
IL134164A (en) 2005-05-17
JP4681116B2 (ja) 2011-05-11
EP1009399A1 (en) 2000-06-21
IL134164A0 (en) 2001-04-30
TW200412938A (en) 2004-08-01
ES2341154T3 (es) 2010-06-15
IS5361A (is) 2000-01-25
HUP0004551A3 (en) 2002-11-28
AU8668598A (en) 1999-03-08
WO1999008671A1 (en) 1999-02-25
TWI251485B (en) 2006-03-21
KR20010023084A (ko) 2001-03-26
NO20000786D0 (no) 2000-02-17
TW570794B (en) 2004-01-11
PE107299A1 (es) 1999-12-19

Similar Documents

Publication Publication Date Title
US6127418A (en) GABA analogs to prevent and treat gastrointestinal damage
US6242488B1 (en) Method for preventing and treating pain
HUP0200344A2 (hu) Gabapentinszármazék alkalmazása visceralis fájdalom megelőzésére és kezelésére
US5763422A (en) Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
JPS60208913A (ja) 高めた無痛覚を与える製薬製品
WO1998013073A9 (en) METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDs AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN
KR20010023745A (ko) 항간질 화합물을 포함하는 진통제 조성물 및 이의 사용 방법
FR2559061A1 (fr) Compositions analgesiques et anti-inflammatoires contenant de la diphenhydramine
EP0974351A2 (en) Medicament for preventing and treating gastrointestinal damage
EP1221950B1 (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
EP1214940B1 (en) Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein
AU2002317548B2 (en) Gaba analogs to prevent and treat gastrointestinal damage
PT97563A (pt) Processo para a preparacao de uma composicao farmaceutica contendo misoprostol e um agente analgesico, por exemplo diclofenac, e metodo para o tratamento da dor utilizando a referida composicao
MXPA00001093A (en) Gaba analogs to prevent and treat gastrointestinal damage
FR3077201A1 (fr) Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
Fernandez et al. Aspirin, salicylate and gastrointestinal
FR2521997A1 (fr) Nouvelle association medicamenteuse a base de morniflumate
Swift et al. A comparison of upper gastrointestinal mucosal damage by standard and delayed‐release indomethacin
ES2277787B1 (es) Empleo de tioprolina en tratamientos de reduccion de peso corporal.
PT2046319E (pt) Antagonistas do receptor da colecistoquinina-1 (cck1) no tratamento de distúrbios gastrointestinais e relacionados
MXPA00001092A (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180820